title: Extrapyramidal side effects during chronic combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys.
abstract: Previous studies in non-human primates have shown that tolerance to dystonia occurs during chronic dopamine D1 (D1) but not D2 antagonism and induction/aggravation of oral dyskinesia (TD) during D2 but not D1 antagonism. We were therefore interested in determining the effects of combined chronic D1 + D2 antagonism on dystonia and dyskinesia. To this intent, 8 male Cebus apella monkeys were treated 10 weeks with gradually increasing doses of D1 antagonist (NNC 112) + a D2 antagonist (raclopride), followed by 2 weeks of treatment with the D2 antagonist alone. Due to previous neuroleptic exposure, 5 monkeys had TD and all were sensitized to dystonia. During the combined antagonist treatment, tolerance to dystonia occurred; the tolerance disappearing upon discontinuation of the D1 antagonist and continuation of the D2 antagonist alone. Parallel to these results, improvement of TD was seen during the combined antagonist treatment with worsening during the D2 antagonist alone. Both the combined antagonists and the D2 antagonist alone resulted in moderate/severe bradykinesia, with no tolerance. These findings indicate that supplementation of traditional D2 antagonism with a D1 antagonist would lessen the risk of dystonia and allow alleviation of preexisting TD, though parkinsonian side effects might still occur. The findings further indicate that separate dopaminergic mechanisms control dystonia/dyskinesia and parkinsonism.
authors.affiliation: Dept. P & Research Institute for Biological Psychiatry, Sct. Hans Hospital, DK-4000 Roskilde, Denmark. lis.nielsen@shh.hosp.dk
authors.forename: L
authors.initials: L
authors.lastname: Peacock
authors.forename: G
authors.initials: G
authors.lastname: Jensen
authors.forename: K
authors.initials: K
authors.lastname: Nicholson
authors.forename: J
authors.initials: J
authors.lastname: Gerlach
mesh_terms: D000818:Animals; D001480:Basal Ganglia Diseases / Q000188:drug therapy*; D001552:Benzazepines / Q000009:adverse effects; D001572:Benzofurans / Q000009:adverse effects; D002428:Cebus; D018492:Dopamine Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D065127:Dopamine D2 Receptor Antagonists; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D008297:Male; D020891:Raclopride / Q000009:adverse effects; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors; D013997:Time Factors
chemical_list: D001552:Benzazepines; D001572:Benzofurans; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D017447:Receptors, Dopamine D1; C077123:NNC 112; D020891:Raclopride